Alexion's Acquisition of Synageva
Scroll to keep reading
Matthew Hurd, Legal counsel to Synageva
Alexion Pharmaceuticals will buy rival Synageva BioPharma in an $8.4 billion cash-and-stock deal that will bolster Alexion’s business in treatments for rare diseases.
Alexion’s takeover offer is aggressive: It will pay $115 in cash and 0.6581 Alexion shares for each share of Synageva, amounting to $230 in cash and stock.
FinanceDLA Piper Advise Olayan's and Mandarin Oriental's Acquirers of Ritz Hotel (€130 million)
FinanceMore than one in three people say they are more likely to give money to charity in the festive season.
NewsThe endless acronyms used in enterprise IT can get overwhelming, but it’s worth knowing about a few lynchpin examples, whether or not your role is technical. Let’s focus on APIs and SDKs, two niches that continue to create evolving opportunities fo
InnovationLaunched in 2018, FashWire is a fashion technology company and premium shopping app marketplace.
NewsCybersecurity has never been something to set once and leave running in the background—it is a constantly evolving landscape. While the migration of data and applications to the cloud provides numerous business benefits, many organisations struggle to secure
NewsCost savings will always remain important for businesses. But business growth today depends more on technology that can adapt and evolve with the business.
NewsMoving to another country can be quite a complicated and challenging process, so it is necessary to prepare well and take into account many factors.
LegalAnyone who has ever driven through a sudden hailstorm knows how jarring it can be. One moment, the road is clear, and the next, ice is pounding against your windshield and roof. The noise is startling, visibility drops fast, and many drivers react without thin
LeadershipScience is moving at a remarkable rate, and no area more so than that of Biotech. This branch of the applied sciences sees specialists harnessing the potential that nature has to offer to benefit mankind. A leader is in this research is the team at Dyna Biotec
Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.
